Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
214 hedge funds and large institutions have $3.21B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 73 increasing their positions, 62 reducing their positions, and 33 closing their positions.
30% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 33
26% more call options, than puts
Call options by funds: $92.8M | Put options by funds: $73.6M
24% more capital invested
Capital invested by funds: $2.58B → $3.21B (+$628M)
18% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 62
4% more funds holding
Funds holding: 205 → 214 (+9)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$123M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$78.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$51M |
| 4 |
Holocene Advisors
New York
|
+$34.4M |
| 5 |
Millennium Management
New York
|
+$32.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$142M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$66.3M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$31.6M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$31.3M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$28.9M |
RETA Hedge Fund Activity: Q2 2023 in Review
214 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q2 2023, worth a combined $3.21B — up 24% from $2.58B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new RETA positions and 33 closed out — a net gain of 10 holders — while 73 added to existing stakes and 62 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $123M. The largest seller was Perceptive Advisors, cutting an estimated $142M.
- 214 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q2 2023, up from 205 in Q1 2023.
- Funds reported $3.21B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q2 2023, up 24% quarter-over-quarter.
- 43 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q2 2023 and 33 closed out, a net change of +10 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q2 2023 was Adage Capital Partners, an estimated $123M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q2 2023 was Perceptive Advisors, an estimated $142M sold.
Based on aggregated 13F filings for Q2 2023.